Previous close | 917.20 |
Open | 911.20 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 911.20 - 956.05 |
52-week range | 850.00 - 1,083.00 |
Volume | |
Avg. volume | 1,883,753 |
Market cap | 766.642B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | 30.46 |
EPS (TTM) | 31.17 |
Earnings date | 10 May 2022 |
Forward dividend & yield | 5.00 (0.53%) |
Ex-dividend date | 09 Aug 2021 |
1y target est | 1,073.39 |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).